Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage.
A 10-year-old girl with paroxysmal nocturnal hemoglobinuria (PNH) received an infusion of syngeneic bone marrow without preparative marrow ablation or immunosuppression. Following transplant, the patient became asymptomatic in concordance with an increase in the percentage of peripheral blood cells with normal expression of glycosyl phosphatidylinositol-anchored proteins (GPI-AP). However, molecular analysis suggested engraftment of a relatively small number of donor stem cells and persistence of an abnormal stem cell with mutant PIG-A. During 17 months of observation, the percentage of cells with normal GPI-AP expression gradually decreased, while intravascular hemolysis progressively increased. Approximately 16.5 months post-transplant, the patient once again became symptomatic. Together, these results indicate that syngeneic marrow infusion provided a clinical benefit by increasing the proportion of erythrocytes with normal expression of GPI-anchored complement regulatory proteins without supplanting the abnormal stem cells. However, evidence of insidious disease progression following the marrow infusion implies that the abnormal stem cells have a survival advantage relative to the transplanted stem cells. Thus, these studies contribute in vivo data in support of the hypothesis that PNH arises as a consequence of a pathological process that selects for hematopoietic stem cells that are GPI-AP-deficient.
Endo
M
M
Department of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Beatty
P G
PG
Vreeke
T M
TM
Wittwer
C T
CT
Singh
S P
SP
Parker
C J
CJ
D016026:Bone Marrow Transplantation; D002470:Cell Survival; D002648:Child; D004200:Diseases in Twins; D004303:Dosage Compensation, Genetic; D004848:Epithelium / Q000648:ultrastructure; D005260:Female; D017261:Glycosylphosphatidylinositols / Q000172:deficiency; D006085:Graft Survival; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood / Q000235:genetics / Q000628:therapy*; D006801:Humans; D008565:Membrane Proteins / Q000172:deficiency / Q000235:genetics; D009061:Mouth Mucosa / Q000648:ultrastructure; D009928:Organ Specificity; D012641:Selection, Genetic; D014184:Transplantation, Homologous; D014430:Twins, Monozygotic; D014960:X Chromosome / Q000235:genetics
D017261:Glycosylphosphatidylinositols; D008565:Membrane Proteins; C080086:phosphatidylinositol glycan-class A protein